Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015

Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: A retrospective claims analysis (2015–2020)

Published:2024-09-10 Issue: Volume: Page:1-15
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Jun Monika P.¹,Mutebi Alex¹,Chhibber Anindit¹,Liang Chenxue²,Keshishian Allison²,Wang Anthony³,Rivas Navarro Fernando⁴,Kalsekar Anupama¹,He Jing¹,Wang Tongsheng¹

Affiliation:

1. Genmab, Plainsboro, NJ

2. Genesis Research, Hoboken, NJ

3. AbbVie, North Chicago, IL

4. Genmab A/S, Copenhagen, Denmark

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2399435

Reference39 articles.

1. Singh R Shaik S Negi BS et al. Non-Hodgkin's lymphoma: A review. J Fam Med Prim Care. 2020;9(4):1834-1840.

2. Cancer Stat Facts: Non-Hodgkin Lymphoma: National Cancer Institute; 2023 [28 Jun 2023]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html. Accessed August 12 2024.

3. Lymphoma - non-Hodgkin: Subtypes: Cancer.Net; 2022 [28 Jun 2023]. Available from: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes. Accessed August 12 2024.

4. Chihara D Johnston K Bolatova T et al. An epidemiological model to estimate the prevalence of diffuse large B-cell lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2022;22(12):e1092-e1099.

5. Cancer stat facts: NHL — diffuse large b-cell lymphoma (DLBCL) Bethesda MD USA: National Institutes of Health National Cancer Institute Surveillance Epidemiology and End Results Program; 2023 [28 Jun 2023]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed August 12 2024.